Treatment of non-constipated irritable bowel syndrome with the histamine 1 receptor antagonist ebastine: a randomised, double-blind, placebo-controlled trial

Conclusions
Our study shows that ebastine is superior to placebo and should be further evaluated as novel treatment for patients with non-constipated IBS.

Trial registration number
The study protocol was approved by the local ethics committee of each study site (EudraCT number: 2013-001199-39; ClinicalTrials.gov identifier: NCT01908465).

Source: Gut - February 23, 2024 Category: Gastroenterology Authors: Decraecker, L., De Looze, D., Hirsch, D. P., De Schepper, H., Arts, J., Caenepeel, P., Bredenoord, A. J., Kolkman, J., Bellens, K., Van Beek, K., Pia, F., Peetermans, W., Vanuytsel, T., Denadai-Souza, A., Belmans, A., Boeckxstaens, G. Tags: Gut Irritable bowel syndrome Source Type: research